Abstract
The incidence of invasive fungal infections (IFIs) has seen a marked increase in the last two decades. This is especially evident among transplant recipients, patients suffering from AIDS, in addition to those in receipt of immunosuppressive therapy. Worryingly, this increased incidence includes infections caused by opportunistic fungi and emerging fungal infections which are resistant to or certainly less susceptible than others to standard antifungal agents. As a direct response to this phenomenon, there has been a resolute effort over the past several decades to improve early and accurate diagnosis and provide reliable screening protocols thereby promoting the administration of appropriate antifungal therapy for fungal infections. Early diagnosis and treatment with antifungal therapy are vital if a patient is to survive an IFI. Substantial advancements have been made with regard to both the diagnosis and subsequent treatment of an IFI. In parallel, stark changes in the epidemiological profile of these IFIs have similarly occurred, often in direct response the type of antifungal agent being administered. The effects of an IFI can be far reaching, ranging from increased morbidity and mortality to increased length hospital stays and economic burden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Blackwell M (2011) The Fungi: 1, 2, 3 … 5.1 million species? Am J Bot 98(3):426–438
Hibbett DS et al (2007) A higher-level phylogenetic classification of the Fungi. Mycol Res 111(5):509–547
Celio GJ et al (2006) Assembling the fungal tree of life: constructing the structural and biochemical database. Mycologia 98(6):850–859
Birren B, Fink G, Lander E. (2004) A white paper for fungal comparative genomics, in fungal genome initiative. Centre for Genome Research, 320 Charles Street, Cambridge
Wiebe V, Karriker M (2005) Therapy of systemic fungal infections: a pharmacologic perspective. Clin Tech Small Anim Pract 20(4): 250–257
May GS, Adams TH (1997) The importance of fungi to man. Genome Res 7(11):1041–1044
Hazen KC (1995) New and emerging yeast pathogens. Clin Microbiol Rev 8(4):462–478
Ainsworth GC (1986) The history of medical and veterinary mycology. Cambridge University Press
Ascioglu S et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34(1):7–14
Denning DW (2004) Antifungals. Where are we headed? Drug plus international http://pharmalicensing.com/articles/disp/1095693369_414ef439d6909
Fridkin SK, Jarvis WR (1996) Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 9(4):499–511
Wheat LJ (2009) Approach to the diagnosis of the endemic mycoses. Clin Chest Med 30(2):379–389
McGinnis MR, Rinaldi MG (1995) Selected medically important fungi and some common synonyms and obsolete names. Clin Infect Dis 21(2):277–278
McGinnis MR, Sigler L, Rinaldi MG (1999) Some medically important fungi and their common synonyms and names of uncertain application. Clin Infect Dis 29(4):728–730
Carrasco L et al (2005) Isolation of Candida famata from a patient with acute zonal occult outer retinopathy. J Clin Microbiol 43(2): 635–640
Naggie S, Perfect JR (2009) Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis. Clin Chest Med 30(2):337–353, vii–viii
Guarner J, Brandt ME (2011) Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 24(2):247–280
Castagnola E et al (2008) Invasive mycoses in children receiving hemopoietic SCT. Bone Marrow Transplant 41(Suppl 2):S107–S111
Castagnola E et al (2007) A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 45(10):1296–1304
Castagnola E et al (2010) Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer 55(6):1103–1107
Murray PR, Rosenthal KS, Pfaller MA (2009) Medical microbiology. 6th edn. Philadelphia, PA, USA, Elsevier Mosby
Oz Y, Kiraz N (2011) Diagnostic methods for fungal infections in pediatric patients: microbiological, serological and molecular methods. Expert Rev Anti Infect Ther 9(3):289–298
Scott LJ, Simpson D (2007) Voriconazole: A review of its use in the management of invasive fungal infections. Drugs 67(2):269–298
Pfaller MA (1996) Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 22(Suppl 2):S89–S94
Pfaller MA et al (2000) Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother 44(3):747–751
Nucci M, Anaissie E (2001) Revisiting the source of Candidemia: skin or gut? Clin Infect Dis 33(12):1959–1967
Strausbaugh LJ et al (1994) High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 32(9):2299–2300
Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1):133–163
Denning DW (2003) Echinocandin antifungal drugs. Lancet 362(9390):1142–1151
Perea S, Patterson TF (2002) Antifungal resistance in pathogenic fungi. Clin Infect Dis 35(9):1073–1080
Krcmery V, Barnes AJ (2002) Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hospital Infect 50(4):243–260
Pfaller MA et al (2006) Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 44(10): 3578–3582
Hay RJ, Jones RM (2010) New molecular tools in the diagnosis of superficial fungal infections. Clin Dermatol 28(2):190–196
Enoch DA, Ludlam HA, Brown NM (2006) Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 55(7):809–818
Rex JH et al (2000) Practice guidelines for the treatment of Candidiasis. Clin Infect Dis 30(4):662–678
Bicanic T, Harrison TS (2004) Cryptococcal meningitis. Br Med Bull 72(1):99–118
Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26(4):781–803
Kontoyiannis, Bodey (2002) Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infecti Dis 21(3):161–172
Kontoyiannis DP, Mantadakis E, Samonis G (2003) Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 53(4):243–258
Patterson TF et al (2000) Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 79(4):250–260
Haiduven D (2009) Nosocomial aspergillosis and building construction. Med Mycol 47(s1):S210–S216
Klont RR, Meis JFGM, Verweij PE (2001) Critical assessment of issues in the diagnosis of invasive aspergillosis. Clin Microbiol Infect 7:32–37
Metcalf SC, Dockrell DH (2007) Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 55(4):287–299
Nelson PE, Dignani MC, Anaissie EJ (1994) Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 7(4): 479–504
Sampathkumar P, Paya CV (2001) Fusarium infection after solid-organ transplantation. Clin Infect Dis 32(8):1237–1240
Thursky KA et al (2008) Recommendations for the treatment of established fungal infections. Intern Med J 38(6b):496–520
Greenberg RN et al (2004) Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 17(6):517–525
Petrikkos G, Drogari-Apiranthitou M (2011) Zygomycosis in immunocompromised nonhaematological patients. Mediterr J Hematol Infect Dis 3(1):e2011012
De Pauw B et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821
Perea S, Patterson TF (2002) Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect 17(2): 99–105
Stevens DA (2002) Diagnosis of fungal infections: current status. J Antimicrob Chemother 49(Suppl 1):11–19
Ellepola AN, Morrison CJ (2005) Laboratory diagnosis of invasive candidiasis. J Microbiol 43:65–84
Posteraro B et al (2011) Update on the laboratory diagnosis of invasive fungal infections. Mediterr J Hematol Infect Dis 3(1):e2011002
Sanguinetti M et al (2007) Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol 45(4):1343–1346
Alexander BD, Pfaller MA (2006) Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 43:S15–S27
Marr KA, Patterson T, Denning D (2002) Aspergillosis. Pathogenesis, clinical manifestations and therapy. Infect Dis Clin North Am 16(4):875–894, vi
Chandrasekar P (2010) Diagnostic challenges and recent advances in the early management of invasive fungal infections. Eur J Haematol 84(4):281–290
Karageorgopoulos DE et al (2011) Beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 52(6):750–770
Cordonnier C et al (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48(8): 1042–1051
Almyroudis NG, Segal BH (2009) Prevention and treatment of invasive fungal diseases in neutropenic patients. Curr Opin Infect Dis 22(4):385–393
Dornbusch HJ, Groll A, Walsh TJ (2010) Diagnosis of invasive fungal infections in immunocompromised children. Clin Microbiol Infect 16(9):1328–1334
Klont RR, Mennink-Kersten MASH, Verweij PE (2004) Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 39(10):1467–1474
Maertens J et al (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97(6):1604–1610
Sanguinetti M et al (2003) Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 41(8):3922–3925
Viscoli C et al (2002) Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 40(4): 1496–1499
Wheat LJ, Walsh TJ (2008) Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis 27(4):245–251
Marr KA et al (2005) Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40(12):1762–1769
Adam O et al (2004) Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 38(6):917–920
Pfeiffer CD, Fine JP, Safdar N (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42(10):1417–1427
Marty FM, Koo S (2009) Role of (1– > 3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 47(Suppl 1):S233–S240
Kohno S et al (1993) An evaluation of serodiagnostic tests in patients with candidemia: beta-glucan, mannan, candida antigen by Cand-Tec and D-arabinitol. Microbiol Immunol 37(3):207–212
Ostrosky-Zeichner L et al (2005) Multicenter clinical evaluation of the (1- > 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41(5):654–659
Odabasi Z et al (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39(2):199–205
Morrissey CO et al (2008) Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy. Intern Med J 38(6b):477–495
Weiner MH, Coats-Stephen M (1979) Immunodiagnosis of systemic candidiasis: mannan antigenemia detected by radioimmunoassay in experimental and human infections. J Infect Dis 140(6):989–993
Yera H et al (2001) Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur J Clin Microbiol Infect Dis 20(12):864–870
Pasqualotto AC, Denning DW (2005) Diagnosis of invasive fungal infections – current limitations of classical methods and new diagnostic methods. Europ Oncol Rev REV:1–11
Hauggaard A, Ellis M, Ekelund L (2002) Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 43(3):292–298
Primack SL et al (1994) Pulmonary nodules and the CT halo sign. Radiology 190(2): 513–515
Pinto PS (2004) The CT halo sign. Radiology 230(1):109–110
Caillot D et al (2001) Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19(1):253–259
Bader O et al (2011) Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect 17:1359–1365
Alanio A et al (2011) Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for fast and accurate identification of clinically relevant Aspergillus species. Clin Microbiol Infect 17(5):750–755
White PL, Perry MD, Barnes RA (2009) An update on the molecular diagnosis of invasive fungal disease. FEMS Microbiol Lett 296(1):1–10
White PL et al (2006) The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 42(4): 479–486
Dunyach C et al (2008) Detection and identification of Candida spp. in human serum by LightCycler real-time polymerase chain reaction. Diagn Microbiol Infect Dis 60(3):263–271
Costa C et al (2002) Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 40(6):2224–2227
Landlinger C, Preuner S, Bašková L, van Grotel M, Hartwig NG, Dworzak M, Mann G, Attarbaschi A, Kager L, Peters C, Matthes-Martin S, Lawitschka A, van den Heuvel-Eibrink MM, Lion T (2010) Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia 24:2032–2038
Khot PD, Fredricks DN (2009) PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther 7(10):1201–1221
Barnes RA (2008) Early diagnosis of fungal infection in immunocompromised patients. J Antimicrob Chemother 61(Suppl 1):i3–i6
Donnelly JP (2006) Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 42(4):487–489
Buchheidt D et al (2004) Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 125(2):196–202
Wheat LJ (2006) Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 8(3):128–139
Mengoli C et al (2009) Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 9(2):89–96
Archibald L et al (1997) Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 24(2):211–215
Ghimire A, Dela Cruz CS (2011) Fungal infections in the intensive care unit. The American College of Chest Physicians. PCCSU. Vol 25
Ruping MJGT, Vehreschild JJ, Cornely OA (2008) Patients at high risk of invasive fungal infections when and how to treat. Drugs 68(14):1941–1962
Viscoli C (2009) Antifungal prophylaxis ans preemptive therapy. Drugs 69(Suppl 1):75–78
Playford EG, Lipman J, Sorrell TC (2010) Management of invasive candidiasis in the intensive careunit. Drugs 70:823–839
Rubio-Terres C, Grau S (2010) Pharma-coeconomics of voriconazole. Expert Opin Pharmacother 11(6):877–887
Ashley ESD et al (2006) Pharmacology of systemic antifungal agents. Clin Infect Dis 43: S28–S39
Loeffler J, Stevens DA (2003) Antifungal drug resistance. Clin Infect Dis 36(Suppl 1): S31–S41
Mohr J et al (2008) Current options in antifungal pharmacotherapy. Pharmacotherapy 28(5):614–645
Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12(2):308–329
Boucher HW et al (2004) Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64(18):1997–2020
Ng AW, Wasan KM, Lopez-Berestein G (2003) Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 6(1):67–83
Kontoyiannis DP et al (2003) Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diagn Microbiol Infect Dis 47(2):415–419
Kauffman CA (2006) Fungal infections. Proc Am Thorac Soc 3(1):35–40
Fluckiger U et al (2006) Treatment options of invasive fungal infections in adults. Swiss Med Wkly 136(29–30):447–463
McCoy D, Depestel DD, Carver PL (2009) Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts. Pharmacotherapy 29:1306–1325
Lai CC et al (2008) Current challenges in the management of invasive fungal infections. J Infect Chemother 14(2):77–85
Letscher-Bru V, Herbrecht R (2003) Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 51(3):513–521
Auberger J, Lass-Flörl C (2011) Current evidence for the treatment of invasive fungal infections in immunocompromised patients. Clin Infect 1(3):447–457
Richardson MD, Jones BL (2007) Therapeutic guidelines in systemic fungal infections. 3rd edn. Current Medical Literature.
Safdar A (2007) Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections. Clin Microbiol Infect 13(1):1–4
İkincioğulları A et al (2005) Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther Apher Dial 9(2):137–141
Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12(4):501–517
Kontoyiannis DP, Lewis RE (2002) Antifungal drug resistance of pathogenic fungi. Lancet 359(9312):1135–1144
Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12(1):40–79
Arikan S (2007) Current status of antifungal susceptibility testing methods. Med Mycol 45(7):569–587
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Tuite, N.L., Lacey, K. (2013). Overview of Invasive Fungal Infections. In: O'Connor, L., Glynn, B. (eds) Fungal Diagnostics. Methods in Molecular Biology, vol 968. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-257-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-257-5_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-256-8
Online ISBN: 978-1-62703-257-5
eBook Packages: Springer Protocols